Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™
- Dec 8, 2022
- 2 min read
Updated: Dec 13, 2022
Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2. In its Phase 1 study DF1001 was well-tolerated and showed encouraging clinical response, with tumor burden reductions across several tumor types including in HER2-low and heavily pre-treated patients.
WALTHAM, MA. December 8, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the Company), a clinical stage biotechnology company developing novel immunotherapies, today announced the first patient dosed in a Phase 1/2 study of the Company’s proprietary EGFR-targeting TriNKET.
DF9001is the sixth Dragonfly-developed drug to enter into clinical trials. The Company’s first TriNKET, DF1001, entered Phase 2 trials this month after being well-tolerated in Phase 1 with encouraging clinical responses, including showing tumor burden reductions across several tumor types, including in HER2-low and heavily pre-treated patients.
“Given our positive experience over the last two years with Dragonfly’s DF1001 HER2-targeting TriNKET, we are excited to begin offering patients with an even broader set of solid tumor cancers this new EGFR-targeting therapeutic,” said Howard P. Safran, MD, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group. “We see an opportunity for Dragonfly’s next generation of NK cell-engaging immune-oncology therapies to attack solid tumor cancers directly, recruit T cells to cold tumor environments, and offer a broadened therapeutic index – helping patients that presently have very few other therapeutic options.”
“Initiating clinical trials with the sixth drug candidate developed by Dragonfly demonstrates how comprehensively we and our Pharma partners are bringing critically-needed new treatment options to patients with cancer,” said Jean-Marie Cuillerot, Dragonfly’s Chief Medical Officer.
Dragonfly Therapeutics’ DF9001 Phase 1/2 clinical trial is a first-in-human, multi-part, open-label, non-randomized, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF9001 alone and in combination with a PD-1 checkpoint inhibitor in patients with locally advanced or metastatic solid tumors, followed by expansion in selected indications including Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal cancer (CRC), and Non-small Cell Lung Cancer (NSCLC).
Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05597839).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:
DRAGONFLY MEDIA CONTACT:
Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Esta plataforma reúne toda la información necesaria sobre loteria nacional en una sola página. Los resultados se muestran de forma clara y ordenada, facilitando la consulta diaria. Su estructura permite acceder rápidamente a los sorteos más recientes y disfrutar de una experiencia sencilla y eficiente.
Mình có lần lướt đọc mấy trao đổi trên mạng شيخ روحاني thì thấy nhắc nên cũng tò mò mở ra xem thử cho biết. Mình không tìm hiểu sâu جلب الحبيب chỉ xem qua trong thời gian ngắn để quan sát bố cục جلب الحبيب cách sắp xếp شيخ روحاني các mục và trình bày nội شيخ روحاني dung tổng thể. Cảm giác là các phần được trình bày khá gọn, các Berlinintim mục rõ ràng nên đọc lướt cũng không bị rối جلب الحبيب với mình như شيخ روحاني vậy là đủ để nắm tin cơ bản rồi. جلب الحبيب
,
,
A significant milestone for the research team and everyone involved in developing new treatment options. Beginning a Phase 1 study requires years of careful work, patience, and persistence—qualities that also come to mind when playing Geometry Dash Lite. Congratulations to the team on reaching this important stage.
Really glad I stumbled across this article today. It covers a lot of ground in a short amount of time and keeps you fully locked in. It’s the perfect thing to check out right before loading up Tiny Fishing
In the modern era of smartphones and digital entertainment, puzzle games have become one of the most popular forms of recreation. They are easy to play, require little preparation, and can be enjoyed by people of all ages. Among the many puzzle games available today, Block Blast has gained significant popularity because of its simple gameplay, colorful design, and challenging mechanics. The game offers an enjoyable experience that combines strategy, logic, and quick decision-making without creating unnecessary pressure on players. Since it is free to download and easy to understand, millions of people around the world play Block Blast during their leisure time.